BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 14, 2011
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Progenics, Salix sales and marketing update

Progenics granted Salix exclusive, worldwide rights to develop and commercialize Relistor methylnaltrexone, excluding Japan. Progenics will receive $60 million up front and is eligible for up to $290 million in milestones, plus royalties. Progenics also will receive 60% of any revenues Salix receives from sublicensing Relistor. The subcutaneous formulation of...

Read the full 239 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >